Page 3 - Pascal Deschatelets News Today

Inspire Advisors LLC reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 50.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,115 shares of the company’s stock after selling 6,342 shares during the period. Inspire […]

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong […]

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy […]

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective cut by Citigroup from $70.00 to $67.00 in a research note published on Friday, Benzinga reports. They currently have a buy rating on the stock. Other analysts have also recently issued reports about the company. Bank of America upgraded Apellis Pharmaceuticals from a neutral rating […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 18,590,000 shares, an increase of 10.9% from the September 30th total of 16,770,000 shares. Based on an average trading volume of 4,170,000 shares, […]

Handelsbanken Fonder AB lifted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 14.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,200 shares of the company’s stock after acquiring an additional 2,200 shares during the period. Handelsbanken Fonder […]

Picton Mahoney Asset Management reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 12.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,727 shares of the company’s stock after selling 6,048 shares […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) will be announcing its earnings results before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last announced its earnings results on Monday, July 31st. The company reported ($1.02) […]

Fiduciary Trust Co. lowered its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 49.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 273,916 shares of the company’s stock after selling 268,375 shares during the quarter. Fiduciary Trust Co.’s holdings in Apellis Pharmaceuticals […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 16,770,000 shares, a growth of 23.2% from the September 15th total of 13,610,000 shares. Based on an average trading volume of 5,100,000 shares, the short-interest ratio […]